Sanofi
- Country
- 🇫🇷France
- Ownership
- Public
- Employees
- 87.9K
- Market Cap
- $141.3B
- Website
- http://www.sanofi.com
- Introduction
Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities. The Consumer Healthcare segment includes the commercial operations for its Consumer Healthcare products. The Vaccines segment consists commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France.
Glimepiride vs Metformin as Monotherapy in Pediatric Subjects With Type 2 Diabetes Mellitus
- Conditions
- Type 2 Diabetes Mellitus
- First Posted Date
- 2006-07-19
- Last Posted Date
- 2011-01-11
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 100
- Registration Number
- NCT00353691
- Locations
- 🇺🇸
Sanofi-Aventis, Bridgewater, New Jersey, United States
Risedronate In The Prevention Of Osteoporosis In Osteopenic Postmenopausal Women
- Conditions
- Osteoporosis, Postmenopausal
- First Posted Date
- 2006-07-17
- Last Posted Date
- 2009-12-15
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 171
- Registration Number
- NCT00353080
- Locations
- 🇸🇪
Sanofi-Aventis, Stockholm, Sweden
Risedronate in Postmenopausal Women With Low Bone Density
- Conditions
- OSTEOPOROSIS, POSTMENOPAUSAL
- First Posted Date
- 2006-07-12
- Last Posted Date
- 2012-02-17
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 150
- Registration Number
- NCT00351091
LANTUSTITR: Insulin Glargine in Type 2 Diabetes Mellitus
- Conditions
- Diabetes Mellitus, Type 2
- First Posted Date
- 2006-07-10
- Last Posted Date
- 2009-12-07
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 4
- Registration Number
- NCT00349986
- Locations
- 🇭🇺
Sanofi-Aventis, Budapest, Hungary
Irbesartan, Ciprofibrate and Their Combination Onto the Endothelial Functions
- Conditions
- DyslipidemiaHypertension
- First Posted Date
- 2006-07-10
- Last Posted Date
- 2008-01-23
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 60
- Registration Number
- NCT00350038
- Locations
- 🇭🇺
Sanofi-aventis, Budapest, Hungary
Lantus in Prediabetes
- Conditions
- HyperglycemiaDiabetes Mellitus
- First Posted Date
- 2006-07-06
- Last Posted Date
- 2006-07-06
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 20
- Registration Number
- NCT00348972
- Locations
- 🇺🇸
Sanofi-Aventis, Bridgewater, New Jersey, United States
Total Hip Replacement Study With XRP4563 (Enoxaparin Sodium)
- Conditions
- Arthroplasty, Replacement, Hip
- First Posted Date
- 2006-07-06
- Last Posted Date
- 2009-03-27
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 156
- Registration Number
- NCT00349180
- Locations
- 🇯🇵
Sanofi-Aventis, Tokyo, Japan
HENOX: Enoxaparine in Hemodialysis
- Conditions
- Hemodialysis
- First Posted Date
- 2006-07-04
- Last Posted Date
- 2008-01-24
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 100
- Registration Number
- NCT00347490
- Locations
- 🇹🇭
Sanofi-Aventis, Bangkok, Thailand
Long Term Safety of SL77.0499-10 (Alfuzosin) in Patients With BPH
- Conditions
- Benign Prostatic Hyperplasia
- First Posted Date
- 2006-07-04
- Last Posted Date
- 2009-10-02
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 148
- Registration Number
- NCT00347061
- Locations
- 🇯🇵
Sanofi-Aventis, Tokyo, Japan
Insulin Glargine in Type 2 Diabetic Patients
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Drug: GlyclazideDrug: Glimiperide
- First Posted Date
- 2006-07-04
- Last Posted Date
- 2009-09-15
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 387
- Registration Number
- NCT00347100
- Locations
- 🇨🇳
Sanofi-Aventis, Beijing, China